IOL Chemicals and Pharmaceuticals' board has approved key strategic moves.

Q1 FY26 consolidated financial results show Revenue from operations at Rs 551.69 Cr and Profit after Tax (PAT) at Rs 33.93 Cr.

The company is setting up a Wholly Owned Subsidiary in the UK to boost its global business and better serve UK/EU customers.

A new Minoxidil manufacturing unit (Unit 9B) with 120 MTPA capacity will be established for Rs 5.50 Cr, fully funded by internal accruals, targeting completion by Dec 2025. This aims to enhance capabilities and product portfolio.